主页 > 生命科学 >
【文摘发布】使用血清AFP修改的评分系统来扩展
Author:Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU.
source:Surgery. 2007 May;141(5):598-609.
IF:2.566(2005)
BACKGROUND: The development of living donor liver transplantation has stimulated discussion about the expansion of tumor burden limits for patients with hepatocellular carcinoma (HCC). Although serum alphafetoprotein (AFP) level is an important predictor of tumor recurrence, it is not included in the existing selection criteria for HCC in transplantation. METHODS: We performed a retrospective study of 63 consecutive adults with HCC diagnosed preoperatively who received living donor liver transplantation from February 1999 to September 2005 and survived over 1 month. The authors devised new scoring criteria that included tumor size, tumor number, and pretransplant AFP level as prognostic factors. The score of each parameter was classified from 1 to 4 points (tumor size, < or =3, 3.1 to 5, 5.1 to 6.5, >6.5 cm; tumor number, 1, 2 or 3, 4 or 5, or > or =6 nodules; and AFP, < or =20, 20.1 to 200, 200.1 to 1000, >1000 ng/mL, respectively). We defined that 3 to 6 points and 7 to 12 points were "transplantable" and "nontransplantable," respectively. The usefulness of the devised criteria was then investigated as a method of selecting candidates with HCC for transplantation. RESULTS: The candidates' overall 3-year survival rate and recurrence-free survival rate were 67% and 70% after transplantation, respectively. Based on pretransplant imaging, 37 (59%), 41 (65%), and 44 (70%) of the 63 patients met the Milan criteria, University of Californica, San Francisco (UCSF) criteria, and the new scoring criteria. Their 3-year survival rates were 80%, 78%, and 79%, respectively. Moreover, based on posttransplant data, the scoring criteria correlated with the risk of death and HCC recurrence (Milan criteria, P = .005 and .001; UCSF criteria, P = .013 and .001 for death and recurrence; scoring criteria, P < .001 for both). CONCLUSIONS: The newly devised scoring criteria could expand usefully current selection criteria for transplantation without detrimentally affecting outcome in the living donor transplantation setting for HCC. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Title: A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
标题：使用血清AFP修改的评分系统来扩展行活体肝移植的肝癌侯选病人
Author:Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU.
作者：Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Kim IH, Yi NJ, Lee KU
source:Surgery. 2007 May;141(5):598-609.
来源：外科学 2007 年 5月 第141卷 第 5期 598-609
IF:2.566(2005)
影响因子 ：2.566 （2005年）
BACKGROUND: The development of living donor liver transplantation has stimulated discussion about the expansion of tumor burden limits for patients with hepatocellular carcinoma (HCC). Although serum alphafetoprotein (AFP) level is an important predictor of tumor recurrence, it is not included in the existing selection criteria for HCC in transplantation.
背景：活体肝移植的发展已经激起关于扩展肝细胞癌患者癌症负荷限制（分期限制）的讨论。尽管血清AFP水平是一个重要的肿瘤复发预测因子，它不包括在肝移植中肝癌患者的选择标准中。
METHODS: We performed a retrospective study of 63 consecutive adults with HCC diagnosed preoperatively who received living donor liver transplantation from February 1999 to September 2005 and survived over 1 month. The authors devised new scoring criteria that included tumor size, tumor number, and pretransplant AFP level as prognostic factors.
方法：我们进行了一项回顾性研究，从1999年到2005年9月， 63例连续的术前诊断为肝细胞、接受活体肝移植、存活超过1个月的成人患者列入研究。作者们设计了包括肿瘤大小、肿瘤数目和移植前AFP水平作为诊断因子的新的评分标准。
The score of each parameter was classified from 1 to 4 points (tumor size, < or =3, 3.1 to 5, 5.1 to 6.5, >6.5 cm; tumor number, 1, 2 or 3, 4 or 5, or > or =6 nodules; and AFP, < or =20, 20.1 to 200, 200.1 to 1000, >1000 ng/mL, respectively). We defined that 3 to 6 points and 7 to 12 points were "transplantable" and "nontransplantable," respectively. The usefulness of the devised criteria was then investigated as a method of selecting candidates with HCC for transplantation.
每个参数的评分分1-4分 (分别为肿瘤大小, 小于或等于3, 3.1 到 5, 5.1 到 6.5, 大于6.5 cm; 肿瘤数目, 1, 2 或 3, 4或 5, 大于或等于6; AFP水平, 小于或等于20, 20.1 到 200, 200.1 到 1000, 大于1000 ng/mL). 然后该标准的作为一种选择进行肝移植的肝细胞癌患者候选人标准，其有效性被研究。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-17 05:12
医学,生命科学网